Cantor Upgrades Capricor to Overweight, PT $28, After HOPE-3 Success and $238M Cash
CAPR has more than doubled off its 52-week low of $2.96 on elevated volume (16× avg).
Summary
Capricor's HOPE-3 Phase 3 trial met its primary endpoint for upper limb function (PUL 2.0, p=0.029), with a cardiomyopathy subgroup benefit (p=0.02), though the post-peer-review LVEF secondary endpoint weakened to p=0.09. The company reported a Q2 adjusted loss of $0.70 per share with zero revenue, but holds approximately $238M in cash, enough for at least 12 months. Cantor Fitzgerald upgraded the stock to Overweight and raised its price target to $28 from $3.50, a significant vote of confidence following the FDA's agreement to review new 24-month data. Non-Deramiocel programs are paused, and regulatory discussions are ongoing in Europe and Japan. This follows the FDA advisory committee's 9-3 negative vote in late July and the subsequent 118% premarket surge on August 14 after the FDA accepted the new data. The PDUFA target action date of August 22, 2026, is the next major catalyst.
At the time of this announcement, CAPR was trading at $6.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $385.1M. The 52-week trading range was $2.96 to $40.37. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.